PD-1 antibody after colon cancer surgery for dMMR stage III
Treatments studied
Part of Cancer, Digestive system clinical trials.
This phase 3 trial studies a PD-1 antibody medicine given after surgery to help prevent stage III colon cancer from coming back. It is specifically for people whose tumor is mismatch repair–defective (dMMR) or MSI-H, which may make the cancer more responsive to immune-based treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have stage III colon adenocarcinoma that was fully removed by surgery with clear margins.
- Tumor must be dMMR or MSI-H, based on special lab tests showing lack of staining for MLH1, MSH2, MSH6, or PMS2.
- Have no spread to other organs on post-surgery CT scan.
- Be able to start planned chemotherapy within 12 weeks after surgery and have had no chemotherapy or radiation before surgery.
- Not be pregnant or breastfeeding, and be able to receive immunotherapy safely (no serious uncontrolled infections, major autoimmune disease flare risk, or severe allergic reaction history).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called PD-1 (a type of immunotherapy that helps your immune system fight cancer), sometimes with chemotherapy, before surgery for a certain type of colorectal cancer. It is for people whose tumors have a specific DNA repair problem (dMMR or MSI-H) and whose cancer has not spread to distant organs.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This trial tests a new immunotherapy drug (AK104) given before and after surgery for a specific type of colon cancer that is MSI-H or dMMR. The goal is to see if the drug helps shrink the tumor and prevent the cancer from coming back.
This Phase 2 trial studies whether adding a PD-1 antibody plus gemcitabine/oxaliplatin (GEMOX) after surgery can lower the chance of the cancer coming back in perihilar cholangiocarcinoma. It’s for people who have had surgery with no tumor left at the cut edges, but lymph nodes showed cancer under the microscope.
This trial tests tislelizumab given after colon cancer surgery to lower the risk of the cancer coming back. It is for people with stage II or III colon cancer that has defective mismatch repair (dMMR).
This trial tests giving PD-1 immunotherapy with chemotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes for patients who haven't had prior cancer treatment.
Hear when a new Colorectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.